Brief: Acticor Biotech Says Clinical Trial In Patients With AIS Showed Favorable Safety Profile Of Glenzocimab

Acticor Biotech SA

31/08/2023 16:53

Aug 31 (Reuters) - Acticor Biotech SA  ALACT.PA :
    * ACTIMIS POST-HOC RESULTS ON IMAGING STROKE DATA USING
ARTIFICIAL
INTELLIGENCE REINFORCES GLENZOCIMAB MODE OF ACTION IN STROKE
PATIENTS
    * ANNOUNCED RESULTS OF ITS COLLABORATION WITH BRAINOMIX
LIMITED,
TO FURTHER EXPLORE IMAGING DATAUSING ARTIFICIAL INTELLIGENCE
(AI) FROM ITS PHASE 1B/2A ACTIMIS STUDY
    * CLINICAL TRIAL IN PATIENTS WITH ACUTE ISCHEMIC STROKE
(AIS)
DEMONSTRATED FAVORABLE SAFETY PROFILE OF GLENZOCIMAB AND
SIGNIFICANT REDUCTION IN NUMBER OF INTRACEREBRAL HEMORRHAGES AND
MORTALITY IN GROUP TREATED WITH GLENZOCIMAB

Source text for Eikon:  ID:nBw4DGGKya 
Further company coverage:  ALACT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))